Celldex Therapeutics, Inc. CLDX

Celldex Therapeutics reports two Phase 3 trials of barzolvolimab in chronic spontaneous urticaria meeting primary and key secondary endpoints at 12 weeks, with durable responses. In EMBARQ-CSU1, weekly urticaria activity scores declined by about 20 points on both doses vs 11 on placebo; EMBARQ-CSU2 showed similar separation. Complete response at Week 12: ~42% on active treatment vs ~9% on placebo; at Week 24, 54% on the 150 mg arm in EMBARQ-CSU2 were symptom-free vs 17.6% placebo. Notably, omalizumab-nonresponders achieved 55.3% complete response at 150 mg, and angioedema improved in 74.3% of EMBARQ-CSU2 patients by Week 12 vs 33.7% placebo. European data suggests durability post-treatment, with up to 64% symptom-free seven months after last dose (Week 76). Celldex preserves a $717.6 million cash balance; expects a 2027 BLA filing after 52 weeks of dosing. Prurigo nodularis failed; atopic dermatitis data due late 2026. Two Phase 3 wins in CSU extend runway toward 2027 BLA and de-risk the asset, but FDA approval and broader applicability remain uncertain.

Celldex Therapeutics announced positive top-line Phase III EMBARQ-CSU results for barzolvolimab in adults with chronic spontaneous urticaria who remain symptomatic on H1 antihistamines. Both dosing regimens met the primary endpoint and key secondary endpoints, with mean UAS7 declines of about 20 points versus ~10 for placebo, sustained or deepening through 24 weeks. Complete responses reached up to 54% at week 24, including up to 55% among omalizumab-refractory patients and up to 74% with complete angioedema control at week 12. Safety over 24 weeks was broadly consistent with earlier data; no new major signals, though neutropenia occurred in 9.1%–11.7% of treated patients and two probable anaphylaxis cases were reported. Celldex plans full data presentation in February and a BLA submission in 2027, with options for two regimens and autoinjector later. Robust Phase III efficacy with two regimens and a clear 2027 BLA pathway could meaningfully boost CLDX, but regulatory and safety risks temper certainty.

Celldex Therapeutics (CLDX) shares rose 8% after topline data from two Phase 3 trials of barzolvolimab in chronic spontaneous urticaria (CSU) showed positive results. In EMBARQ-CSU1 and EMBARQ-CSU2, both doses (150 mg and 300 mg) met the primary endpoint, a mean change in weekly urticaria activity score (UAS7) at Week 12, with differences versus placebo highly significant. Complete response rates (UAS7 = 0) also rose, reaching near 50–55% for the 150 mg dose by Week 24. Benefits extended to patients with omalizumab-refractory CSU and those with angioedema. The safety profile remained consistent with earlier studies through 24 weeks. Both trials are ongoing through Week 52. Celldex plans a Biologics License Application to the FDA in 2027, positioning the program as the largest CSU effort in antihistamine-refractory patients. Two Phase 3 trials met primary endpoints and improved complete response rates, supporting a potential BLA submission and meaningful upside.

Barzolvolimab met primary endpoints in two pivotal Phase 3 trials for chronic spontaneous urticaria, signaling potential regulatory approval for Celldex Therapeutics' candidate. Positive top-line results could advance development and strategic options, though details on safety, dosing, and submission timelines were not provided. Two Phase 3 CSU trials meeting endpoints could materially boost regulatory odds and investor sentiment.

Celldex reported positive topline results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 evaluating barzolvolimab in chronic spontaneous urticaria (CSU). Both trials met primary endpoint (mean change in weekly UAS7 at Week 12) and all key secondary endpoints across two dosing regimens (150 mg Q4W after a 300 mg loading dose; 300 mg Q8W after 450 mg loading dose). Efficacy was rapid, profound, and sustained through Week 24, with higher proportions achieving Complete Response (UAS7=0) versus placebo at Weeks 12 and 24, including omalizumab-refractory CSU. Barzolvolimab was well tolerated through 24 weeks; safety aligns with prior data. Treatment continues to 52 weeks; BLA submission planned for 2027. A webcast is planned; Celldex aims to establish barzolvolimab as a potential transformational therapy for CSU. Phase 3 results show large, durable efficacy and an approved path to regulatory filing, with potential to redefine CSU treatment.

Celldex Therapeutics' shares slid about 11% on Tuesday after news that its Barzolvolimab Phase 3 CSU programs met primary and key secondary endpoints, with week-12 complete response 42-46% vs 9-13% placebo and week-24 54% in CSU patients. A Wainwright analyst raised the price target to $64 from $42 with a Buy rating, implying ~90% upside, and Celldex plans a FDA BLA submission in 2027. Despite strong efficacy, investors focused on safety data: two probable Grade 4 anaphylaxis cases, one after placebo. The company defended safety signals as misplaced, arguing the results are robust. The stock initially fell before some recovery; retail sentiment on Stocktwits turned bullish amid high volume. The results support a potential future, but safety concerns persist and regulatory risk remains ahead of the BLA filing. Phase 3 results met primary and key secondary endpoints, but two probable Grade 4 anaphylaxis cases triggered safety concerns and a stock decline.

Celldex Therapeutics (CLDX) may be 130% undervalued following its second quarter results. Q2 results point to major undervaluation that could significantly shift CLDX investor sentiment and trajectory.

Celldex Therapeutics faces growing losses paired with minimal revenue, raising questions if the situation reflects deliberate strategic spending or points to deeper structural weaknesses in its operations. Persistent losses with scant revenue may pressure near-term investor sentiment and valuation but are unlikely to shift the company's fundamental development trajectory.

Celldex Therapeutics issues mixed pipeline update that creates uncertainty around key drug programs and next development steps. Pipeline updates directly affect clinical timelines, regulatory prospects and valuation for a clinical-stage biotech.

Celldex Therapeutics scraps all PN development plans after barzolvolimab misses primary endpoints in its Phase 2 trial. Barzolvolimab Phase 2 failure forces abandonment of a core program and sharply weakens Celldex pipeline prospects and market position.

Celldex drug fails skin disease study. Failed clinical study creates major setback for Celldex drug pipeline and investor outlook.

Celldex Therapeutics released Phase 2 study results for Barzolvolimab in Prurigo Nodularis. Phase 2 Barzolvolimab data in Prurigo Nodularis can materially shift Celldex pipeline value and investor outlook.

CLDX shares fall 10% in after-hours trading amid an unexplained selloff. After-hours share-price drop of this size can shift near-term sentiment and valuation without altering core fundamentals.

Celldex presented long-term barzolvolimab results at the European Academy of Allergy and Clinical Immunology meeting demonstrating sustained off-treatment improvement in angioedema for chronic spontaneous urticaria patients. Long-term efficacy data for barzolvolimab in CSU supports pipeline advancement and potential market positioning.

Celldex Therapeutics presented positive first-in-human Phase 1 results for its novel bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting. Positive Phase 1 data on CDX-622 strengthens Celldex pipeline and investor sentiment.

Celldex Therapeutics reported first quarter 2023 financial results, including cash position of $193.5 million and R&D expenses of $28.4 million, alongside corporate updates on barzolvolimab Phase 2 trials in chronic spontaneous urticaria and atopic dermatitis, with topline data expected mid-2024, and ongoing immuno-oncology programs. Q1 financial results and pipeline updates on barzolvolimab trials affect financial performance and clinical progress but are part of ongoing developments.

Wall Street analysts forecast a 76.42% upside for Celldex Therapeutics (CLDX) stock, questioning if it can realistically reach that level. Analyst price targets signaling 76.42% upside for CLDX could noticeably influence investor sentiment and short-to-medium term market performance.

Celldex Therapeutics spotlights barzolvolimab as Phase III chronic spontaneous urticaria data readout approaches after rapid enrollment. Fast Phase III enrollment for barzolvolimab signals major potential advancement in CSU, likely boosting Celldex's market position and investor sentiment.

Celldex Therapeutics closed its public offering of common stock, with underwriters fully exercising their option to purchase additional shares. Successful public offering raises substantial capital to fund clinical development and bolsters financial runway.

Celldex Therapeutics (CLDX) shares plunged after the company abandoned a $300 million stock offering. Abandoning a $300 million stock deal triggered a share plunge, severely impacting funding prospects and investor confidence.

Celldex Therapeutics priced a US$300 million follow-on offering to fund Barzolvolimab development in mast cell-mediated diseases, sparking debate on whether it strengthens or dilutes the CLDX investment case amid ongoing Phase 2 trials. $300 million infusion directly funds Barzolvolimab's Phase 3 trials and runway extension, marking a major strategic boost to pipeline and valuation trajectory.

Celldex Therapeutics, Inc. (CLDX) announces pricing of a $300 million public offering of common stock. A $300 million public offering provides substantial capital to fund clinical programs and extend runway, significantly impacting financial position and market performance.

Celldex Therapeutics, Inc. (CLDX) announced a proposed public offering of its common stock to raise capital. Proposed public stock offering enables capital raise for operations but dilutes shareholders and typically pressures stock price significantly.

Celldex Therapeutics presented positive Phase 2 data at AAD 2026 from studies in chronic spontaneous urticaria, cold urticaria, and symptomatic dermographism, demonstrating rapid, profound, and durable improvements in patient quality of life. Positive Phase 2 results across three urticaria indications highlight barzolvolimab's efficacy, significantly advancing Celldex's dermatology pipeline and enhancing market prospects.

Celldex Therapeutics highlights strong momentum in Phase III trial of barzolvolimab for chronic spontaneous urticaria and outlines key 2026 data catalysts. Phase III momentum in barzolvolimab for CSU and 2026 catalysts signal major pipeline advancements likely to drive significant investor interest and valuation uplift.

Celldex Therapeutics announced Phase 3 successes for barzolvolimab in chronic spontaneous urticaria and new trials in additional indications at the TD Cowen Conference. Phase 3 wins for barzolvolimab fundamentally transform Celldex's competitive position with a path to approval and expanded pipeline opportunities.

Celldex Therapeutics presented positive data at AAAAI 2026 showing barzolvolimab retreatment delivers similar profound efficacy to initial treatment in patients with Cold Urticaria and Symptomatic Dermographism, further confirming its first-in-class and best-in-disease profile. Positive retreatment data reinforces barzolvolimab's efficacy in urticaria indications, boosting Celldex's pipeline value and investor confidence ahead of potential approvals.

Celldex Therapeutics presented additional positive Phase 2 data from chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) studies on barzolvolimab at AAAAI 2026, further demonstrating its first-in-class and best-in-disease profile. Positive Phase 2 data across multiple urticaria indications reinforces barzolvolimab's competitive edge, likely driving significant pipeline progress and investor enthusiasm for Celldex.

Celldex Therapeutics (CLDX) stock surged 46% over the past year, prompting analysis on whether its current pricing fully reflects this performance and the upside potential indicated by discounted cash flow (DCF) models. Highlighting a 46% stock surge and DCF upside potential moderately influences investor sentiment and valuation perceptions for CLDX.

Celldex Therapeutics released Q4 earnings snapshot highlighting financial results. Q4 earnings snapshots provide key financial metrics that moderately influence investor sentiment and short-term market performance.